Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study.

Autor: Matarraz S; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. smats@usal.es.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain. smats@usal.es., Leoz P; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Yeguas-Bermejo A; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., van der Velden V; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Bras AE; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Sánchez Gallego JI; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Lecrevisse Q; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Ayala-Bueno R; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Teodosio C; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Criado I; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., González-González M; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Flores-Montero J; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Avendaño A; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Vidriales MB; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Chillón MC; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., González T; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., García-Sanz R; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Prieto Conde MI; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Villamor N; Hematology Service, Hospital Clinic, Barcelona, Spain., Magnano L; Hematology Service, Hospital Clinic, Barcelona, Spain., Colado E; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Fernández P; FACS/Stem Cell Laboratory, Kantonsspital Aarau, Aarau, Switzerland., Sonneveld E; Dutch Childhood Oncology Group, The Hague, The Netherlands., Philippé J; Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium., Reiterová M; CLIP-Department of Pediatric Hematology and Oncology, Second Medical Faculty, Charles University and University Hospital Motol, Prague, Czech Republic., Caballero Berrocal JC; Department of Hematology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Diaz-Gálvez FJ; Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain., Ramos F; Department of Hematology, Complejo Asistencial Universitario de León, León, Spain., Dávila Valls J; Department of Hematology, Complejo Asistencial de Ávila, Ávila, Spain., Manjón Sánchez R; Department of Hematology, Complejo Asistencial de Zamora, Zamora, Spain., Solano Tovar J; Department of Hematology, Complejo Asistencial Universitario de Palencia, Palencia, Spain., Calvo X; Pathology Service, Hospital del Mar, Barcelona, Spain., García Alonso L; Hematology Service, University Hospital of Getafe, Madrid, Spain., Arenillas L; Pathology Service, Hospital del Mar, Barcelona, Spain., Alonso S; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Fonseca A; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Quirós Caso C; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., van Dongen JJM; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Orfao A; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. orfao@usal.es.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain. orfao@usal.es.

Publikováno v: Blood cancer journal [Blood Cancer J] 2023 Sep 04; Vol. 13 (1), pp. 132. Date of Electronic Publication: 2023 Sep 04.

Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.

Autor: Aguilera-Diaz A; Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Vazquez I; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., Ariceta B; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., Mañú A; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., Blasco-Iturri Z; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., Palomino-Echeverría S; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., Larrayoz MJ; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., García-Sanz R; Hematology Department, University Hospital of Salamanca, IBSAL and CIBERONC, Salamanca, Spain., Prieto-Conde MI; Hematology Department, University Hospital of Salamanca, IBSAL and CIBERONC, Salamanca, Spain., Del Carmen Chillón M; Hematology Department, University Hospital of Salamanca, IBSAL and CIBERONC, Salamanca, Spain., Alfonso-Pierola A; Hematology Department, Clinica Universidad de Navarra (CUN), Pamplona, Spain., Prosper F; Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Hematology Department, Clinica Universidad de Navarra (CUN), Pamplona, Spain., Fernandez-Mercado M; Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.; Biomedical Engineering Department, School of Engineering, University of Navarra, San Sebastian, Spain., Calasanz MJ; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.; Scientific Co-Director of CIMA LAB Diagnostics, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Publikováno v: PloS one [PLoS One] 2020 Jan 24; Vol. 15 (1), pp. e0227986. Date of Electronic Publication: 2020 Jan 24 (Print Publication: 2020).

A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients.

Autor: Prieto-Conde MI; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Corchete LA; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., García-Álvarez M; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Jiménez C; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Medina A; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Balanzategui A; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Hernández-Ruano M; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Maldonado R; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Sarasquete ME; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Alcoceba M; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Puig N; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., González-Calle V; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., García-Sanz R; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain. Electronic address: rgarcias@usal.es., Gutiérrez NC; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., González-Díaz M; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Chillón MC; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.

Publikováno v: The Journal of molecular diagnostics : JMD [J Mol Diagn] 2020 Jan; Vol. 22 (1), pp. 60-71. Date of Electronic Publication: 2019 Oct 09.

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia.

Autor: Pallarès V; Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. mpallaresl@santpau.cat.; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas nº 90, 08041 Barcelona, Spain. mpallaresl@santpau.cat., Hoyos M; Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. mhoyos@santpau.cat.; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas nº 90, 08041 Barcelona, Spain. mhoyos@santpau.cat., Chillón MC; Servicio de Hematología, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer (CIC)-IBMCC, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Universidad de Salamanca, 37007 Salamanca, Spain. chillon@usal.es., Barragán E; Hematology Department, Hospital Universitari i Politècnic La Fe, Department of Medicine, University of Valencia, and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, 46026 Valencia, Spain. barragan_eva@gva.es., Prieto Conde MI; Servicio de Hematología, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer (CIC)-IBMCC, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Universidad de Salamanca, 37007 Salamanca, Spain. i.prietoconde@usal.es., Llop M; Hematology Department, Hospital Universitari i Politècnic La Fe, Department of Medicine, University of Valencia, and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, 46026 Valencia, Spain. llop_mar@gva.es., Falgàs A; Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. AFalgas@santpau.cat., Céspedes MV; Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. mcespedes@santpau.cat.; CIBER en Bioinginiería, Biomateriales y Nanomedicina (CIBER-BBN), 08025 Barcelona, Spain. mcespedes@santpau.cat., Montesinos P; Hematology Department, Hospital Universitari i Politècnic La Fe, Department of Medicine, University of Valencia, and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, 46026 Valencia, Spain. montesinos_pau@gva.es., Nomdedeu JF; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas nº 90, 08041 Barcelona, Spain. jnomdedeu@santpau.cat., Brunet S; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas nº 90, 08041 Barcelona, Spain. sbrunet@santpau.cat., Sanz MÁ; Hematology Department, Hospital Universitari i Politècnic La Fe, Department of Medicine, University of Valencia, and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, 46026 Valencia, Spain. msanz@uv.es., González-Díaz M; Servicio de Hematología, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer (CIC)-IBMCC, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Universidad de Salamanca, 37007 Salamanca, Spain. margondi@usal.es., Sierra J; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas nº 90, 08041 Barcelona, Spain. jsierra@santpau.cat.; Josep Carreras Leukemia Research Institute, 08021 Barcelona, Spain. jsierra@santpau.cat.; Hematology Department, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain. jsierra@santpau.cat., Mangues R; Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. rmangues@santpau.cat.; CIBER en Bioinginiería, Biomateriales y Nanomedicina (CIBER-BBN), 08025 Barcelona, Spain. rmangues@santpau.cat.; Josep Carreras Leukemia Research Institute, 08021 Barcelona, Spain. rmangues@santpau.cat., Casanova I; Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. icasanova@santpau.cat.; CIBER en Bioinginiería, Biomateriales y Nanomedicina (CIBER-BBN), 08025 Barcelona, Spain. icasanova@santpau.cat.; Josep Carreras Leukemia Research Institute, 08021 Barcelona, Spain. icasanova@santpau.cat.

Publikováno v: Cancers [Cancers (Basel)] 2018 Nov 13; Vol. 10 (11). Date of Electronic Publication: 2018 Nov 13.

Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study.

Autor: Jiménez C; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain., Prieto-Conde MI; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain., García-Álvarez M; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain., Alcoceba M; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Center for Biomedical Research in Network of Cancer (CIBERONC), Salamanca, Spain., Escalante F; Hematology Department, Hospital Complex of León, León, Spain., Chillón MDC; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Center for Biomedical Research in Network of Cancer (CIBERONC), Salamanca, Spain., García de Coca A; Hematology Department, University Clinical Hospital of Valladolid, Valladolid, Spain., Balanzategui A; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain., Cantalapiedra A; Hematology Department, Río Hortega University Hospital, Valladolid, Spain., Aguilar C; Hematology Department, Santa Bárbara Hospital, Soria, Spain., Corral R; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain., González-López T; Hematology Department, Hospital Complex of Burgos, Burgos, Spain., Marín LA; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain., Bárez A; Hematology Department, Nuestra Señora de Sonsoles Hospital, Ávila, Spain., Puig N; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain., García-Mateo A; Hematology Department, General Hospital of Segovia, Segovia, Spain., Gutiérrez NC; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain., Sarasquete ME; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Center for Biomedical Research in Network of Cancer (CIBERONC), Salamanca, Spain., González M; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. margondi@usal.es.; Center for Biomedical Research in Network of Cancer (CIBERONC), Salamanca, Spain. margondi@usal.es., García-Sanz R; Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Center for Biomedical Research in Network of Cancer (CIBERONC), Salamanca, Spain.

Publikováno v: Annals of hematology [Ann Hematol] 2018 Mar; Vol. 97 (3), pp. 475-484. Date of Electronic Publication: 2018 Jan 20.